EC
HRMY icon

EntryPoint Capital’s Harmony Biosciences HRMY Stock Holding History

EntryPoint Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Sell
9,239
-15,025
-62% -$474K 0.08% 497
2026
Q1 		$680K Buy
24,264
+16,578
+216% +$544K 0.2% 150
2025
Q4 		$288K Buy
7,686
+107
+1% +$3.52K 0.11% 378
2025
Q3 		$209K Sell
7,579
-4,717
-38% -$162K 0.08% 537
2025
Q2 		$389K Sell
12,296
-474
-4% -$15.2K 0.19% 176
2025
Q1 		$424K Sell
12,770
-19,314
-60% -$692K 0.19% 162
2024
Q4 		$1.1M Buy
+32,084
New +$1.1M 0.46% 2
2024
Q3 		– Sell
-4,271
Closed -$129K – 939
2024
Q2 		$129K Buy
4,271
+363
+9% +$10.9K 0.06% 667
2024
Q1 		$131K Sell
3,908
-941
-19% -$30.2K 0.12% 286
2023
Q4 		$157K Buy
+4,849
New +$135K 0.15% 169

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EntryPoint Capital's HRMY Position: Q2 2026 in Review

EntryPoint Capital reduced its Harmony Biosciences (HRMY) stake by 62% in Q2 2026, selling an estimated $474K and leaving 9,239 shares worth $336K. The position accounts for 0.08% of the portfolio, ranked #497.

EntryPoint Capital first reported a position in HRMY in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.1M in Q4 2024. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • EntryPoint Capital held 9,239 shares of Harmony Biosciences worth $336K as of Q2 2026.
  • EntryPoint Capital sold 15,025 Harmony Biosciences shares in Q2 2026, an estimated $474K.
  • Harmony Biosciences made up 0.08% of EntryPoint Capital's portfolio in Q2 2026, its #497 holding.
  • EntryPoint Capital first reported a position in Harmony Biosciences in Q4 2023 and has held it in 10 quarters since.
  • EntryPoint Capital's Harmony Biosciences position peaked at $1.1M in Q4 2024.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.